Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension
Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension
复制标题
DOI：
10.1111/j.1538-7836.2007.02394.x
复制
发表时间：
2007-03-01
影响因子：
10.4
通讯作者：
Lang, I. M.
中科院分区：
文献类型：
--
作者：
Skoro-Sajer, N.;Bonderman, D.;Lang, I. M.
背景：慢性血栓栓塞性肺动脉高压（CTEPH）是由血浆抗凝治疗无效的肺血栓栓塞引起的。由于继发性肺动脉病变伴大血管阻塞，这种疾病可能是血管扩张剂治疗的目标。目的：在一项开放标签非对照研究中，我们研究了前列环素类似物treprostiil在严重不能手术的CTEPH患者中的应用。方法：1999年9月~ 2005年9月，25例世界卫生组织（WHO）功能分级为III或IV级，6分钟步行距离（6-MWD）为
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) results from non-resolving pulmonary thromboemboli that are resistant to plasmatic anticoagulation. Because of a secondary pulmonary arteriopathy accompanying major vessel obstruction, the disorder may be a target for vasodilator therapy. Objectives: In an open-label uncontrolled study, we investigated the prostacyclin analog treprostinil given s.c. in patients with severe inoperable CTEPH. Methods: Between September 1999 and September 2005, 25 patients were included if their World Health Organization (WHO) functional class was III or IV, if their six-minute walking distance (6-MWD)